Galera Therapeutics, Inc. (GRTX)の価格はいくらですか

Galera Therapeutics, Inc. (GRTX)の価格は$17.15です

Galera Therapeutics, Inc. (GRTX)の時価総額は何ですか

Galera Therapeutics, Inc. (GRTX)の時価総額は$6.51Mです

Galera Therapeutics, Inc. (GRTX) の利益

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.

年	利益	変化
2026 (TTM)	$149.04M	-877.84%
2024	$-19.16M	-67.57%
2023	$-59.08M	-5.15%
2022	$-62.29M	-22.65%
2021	$-80.53M	8.49%
2020	$-74.23M	42.93%
2019	$-51.94M	117.33%
2018	$-23.90M	-0.03%
2017	$-23.91M	0.00%

年

利益

変化

2026 (TTM)

$149.04M

-877.84%

2024

$-19.16M

-67.57%

2023

$-59.08M

-5.15%

2022

$-62.29M

-22.65%

2021

$-80.53M

8.49%

2020

$-74.23M

42.93%

2019

$-51.94M

117.33%

2018

$-23.90M

-0.03%

2017

$-23.91M

0.00%

企業	利益	利益の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	3,439.37%	US
Argenx SE ARGX.US	$1.95B	1,208.85%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	1,916.79%	BE

企業

利益

利益の差

国